Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body‐size effect

• Asıl Yazarlar: Zheyi Hu (Yazar), Sihang Liu (Yazar), Yue Zhao (Yazar), Shengnan Du (Yazar), Lora Hamuro (Yazar), Jun Shen (Yazar), Amit Roy (Yazar), Li Zhu (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2024-03-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Body size has historically been considered the primary source of difference in the pharmacokinetics (PKs) of monoclonal antibodies (mAbs) between children aged greater than or equal to 2 years and adults. The contribution of age‐associated differences (e.g., ontogeny) beyond body‐size diffe...